If you’ve ever said “it’s just a phase” or “they grow up so fast” about a child—and God knows we have— keep in mind that those phrases also apply to clinical candidates like the lead EpicentRx oncolytic adenovirus, AdAPT-001, which is armed with a TGF-β trap to relieve tumor immunosuppression. We remember not so long ago when AdAPT-001—pun intended—was just the “germ” of an idea in the minds of its co-creators, Drs. Tony Reid, and Chris Larson, well before it became a bona fide clinical candidate.
Now AdAPT-001 has advanced all the way to a Phase 2 trial in combination with a checkpoint inhibitor—how time flies and they really do grow up so fast, don’t they?—after successful “graduation” from a Phase 1 dose escalation clinical trial led by Dr. Anthony Conley at the MD Anderson Cancer Center (MDACC). Read—or, rather, Reid in honor of Dr. Tony Reid, co-creator of AdAPT-001—about the promising safety and activity results from the Phase 1 clinical trial in the well-respected Nature journal, Cancer Gene Therapy, here. Sarcoma specialist, Dr. Anthony Conley, and Principal Investigator from MDACC is the lead author on the manuscript.
As proof that time flies, a manuscript that presents even more compelling data from a Phase 2 trial of AdAPT-001 plus a checkpoint inhibitor is in draft.
Groucho Marx may have said it best: “Time flies like an arrow. Fruit flies like a banana.”